Company: VCYT
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001384101-25-000060
Chunk: 85

Company: VERACYTE, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 85
---
067 $11,918 $1,149 10 %Sample collection expense2,825 3,057 (232)(8)%Compensation expense5,611 5,215 396 8 %Cytopathology services1,455 1,373 82 6 %Depreciation and amortization430 427 3 1 %Other expenses1,500 1,046 454 43 %Allocations3,372 2,943 429 15 %Total$28,260 $25,979 $2,281 9 %Cost of product revenue:    Product costs$109 $1,263 $(1,154)(91)%License fees and royalties324 436 (112)(26)%Depreciation and amortization178 225 (47)(21)%Other expenses614 599 15 3 %Allocations197 121 76 63 %Total$1,422 $2,644 $(1,222)(46)%Cost of biopharmaceutical and other revenue:    Compensation expense$1,240 $1,462 $(222)(15)%License fees and royalties— 149 (149)(100)%Depreciation and amortization48 78 (30)(38)%Other expenses996 722 274 38 %Allocations414 427 (13)(3)%Total$2,698 $2,838 $(140)(5)%Intangible asset amortization - cost of revenue$2,585 $2,915 $(330)(11)%

Cost of testing revenue increased $2.3 million, or 9%, for the three months ended March 31, 2025 compared to the same period in 2024. The increase in cost of testing revenue was due to increased volume in testing, higher staffing to support testing performance and the build out of infrastructure related to current and future growth expectations, primarily related to Decipher Prostate and Afirma tests.

Cost of product revenue decreased $1.2 million, or 46%, for the three months ended March 31, 2025 compared to the same period in 2024, driven by lower costs associated with the transition of manufacturing our IVD kits to our Marseille, France facilities and lower consumption of inventory.

Cost of biopharmaceutical and other revenue includes labor costs, laboratory supplies and pass-through expenses incurred.